IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• IQVIA Holdings Inc. has received a consensus recommendation of "Moderate Buy" from analysts, with 17 out of 23 analysts issuing buy ratings and an average price target of $228.62.
• Insider selling has been reported, with Keriann Cherofsky and Eric Sherbet reducing their ownership by 15.87% and 17.59% respectively on July 23rd, raising questions about insider sentiment.
• The company reported $4.02 billion in revenue for the latest quarter, beating analyst estimates, and has a projected 10.84 earnings per share for the current year.

Shares of IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $228.6190.

A number of equities research analysts have recently weighed in on IQV shares. Truist Financial lifted their price objective on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on IQVIA in a research report on Friday, May 23rd. William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Cowen reiterated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, HSBC lowered IQVIA from a "buy" rating to a "hold" rating and cut their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Institutional Trading of IQVIA

Institutional investors and hedge funds have recently modified their holdings of the business. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in shares of IQVIA in the 1st quarter worth $33,000. Finally, ST Germain D J Co. Inc. grew its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

IQV opened at $190.08 on Thursday. The stock's 50 day simple moving average is $168.77 and its 200 day simple moving average is $169.04. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The firm has a market cap of $32.31 billion, a price-to-earnings ratio of 27.51, a PEG ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the company earned $2.64 EPS. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts predict that IQVIA will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.